• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Luna Innovations Incorporated

    10/29/24 4:10:15 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email
    SC 13D/A 1 p24-3084sc13da.htm LUNA INNOVATIONS INCORPORATED
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Luna Innovations Incorporated

    (Name of Issuer)
     

    Common stock, par value $0.001 per share

    (Title of Class of Securities)
     

    550351100

    (CUSIP Number)
     
    David J. Chanley
    c/o White Hat Capital Partners LP
    520 Madison Avenue, 33rd Floor
    New York, New York 10022
    (212) 257-5940
     
    With a copy to:
     

    Eleazer Klein, Esq.

    David A. Curtiss, Esq.

    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    October 25, 2024

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     

    (Page 1 of 14 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 2 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    White Hat Lightning Opportunity LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (as defined in Item 4 below) (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s) (as defined in Item 4))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.3%*

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    *The conversion of the shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker (as defined in Item 4 below). The number of shares of Common Stock in rows (8), (10) and (11) and the percentage set

    forth in row (13) reflect the conversion in full of the Series B Convertible Preferred Stock reported on this cover page, however, the ability to convert such Series B Convertible Preferred Stock at any given time is subject to the Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.

     

    CUSIP No. 550351100SCHEDULE 13D/APage 3 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    WH Lightning GP LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    831,270 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 113,432 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.3%*

    14

    TYPE OF REPORTING PERSON

    OO

             

     

    * The conversion of the shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker. The number of shares of Common Stock in rows (8), (10) and (11) and the percentage set forth in row (13) reflect the

    conversion in full of the Series B Convertible Preferred Stock reported on this cover page, however, the ability to convert such Series B Convertible Preferred Stock at any given time is subject to the Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.

     

    CUSIP No. 550351100SCHEDULE 13D/APage 4 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    White Hat Strategic Partners II LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.5%*

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    * The conversion of the shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker. The number of shares of Common Stock in rows (8), (10) and (11) and the percentage set forth in row (13) reflect the

    conversion in full of the Series B Convertible Preferred Stock reported on this cover page, however, the ability to convert such Series B Convertible Preferred Stock at any given time is subject to the Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.

     

    CUSIP No. 550351100SCHEDULE 13D/APage 5 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    White Hat SP GP II LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,246,908 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 170,149 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.5%*

    14

    TYPE OF REPORTING PERSON

    OO

             

     

    * The conversion of the shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker. The number of shares of Common Stock in rows (8), (10) and (11) and the percentage set forth in row (13) reflect the

    conversion in full of the Series B Convertible Preferred Stock reported on this cover page, however, the ability to convert such Series B Convertible Preferred Stock at any given time is subject to the Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.

     

    CUSIP No. 550351100SCHEDULE 13D/APage 6 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    White Hat Structured Opportunities LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    *The conversion of the shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number

    shares of Common Stock that would be issuable upon the conversion of the shares of Series B Convertible Preferred Stock in full and does not give effect to the Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 7 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    WHSO GP LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    8,312,724 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,134,328 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    OO

             

     

    *The conversion of shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon the conversion of the shares of Series B Convertible Preferred

    Stock in full and does not give effect to the Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 8 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    White Hat Capital Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    *The conversion of shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of

    shares of Common Stock that would be issuable upon the conversion of the shares of Series B Convertible Preferred Stock in full and does not give effect to the Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 9 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    David J. Chanley

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Stated of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    IN

             

     

    *The conversion of shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of

    shares of Common Stock that would be issuable upon the conversion of the shares of Series B Convertible Preferred Stock in full and does not give effect to the Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 10 of 14 Pages

     

    1

    NAME OF REPORTING PERSON

    Mark R. Quinlan

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,390,902 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock (including 1,417,909 shares of Common Stock issuable upon conversion of shares of Series B Convertible Preferred Stock issuable in one or more Subsequent Issuance(s))*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.99%*

    14

    TYPE OF REPORTING PERSON

    IN

             

     

    *The conversion of shares of Series B Convertible Preferred Stock reported herein is subject to the Blocker and the percentage set forth in row (13) gives effect to the Blocker. However, rows (8), (10) and (11) show the number of

    shares of Common Stock that would be issuable upon the conversion of the shares of Series B Convertible Preferred Stock in full and does not give effect to the Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the Blocker, is less than the number of securities reported in rows (8), (10) and (11).

     

    CUSIP No. 550351100SCHEDULE 13D/APage 11 of 14 Pages

    The following constitutes Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D filed by the undersigned with the Securities and Exchange Commission on December 27, 2023 (the “Original Schedule 13D”), as amended by Amendment No. 1 to the Original Schedule 13D filed by the undersigned with the Securities and Exchange Commission on July 23, 2024 (“Amendment No. 1,” and the Original Schedule 13D as amended by Amendment No. 1 and this Amendment No. 2, the “Schedule 13D”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
       
    Item 3 of the Schedule 13D is hereby amended and supplemented to include the following:
     
      The White Hat Funds acquired the 3,000 Additional Shares (as defined below) reported herein in exchange for the Preferred Consent (as defined below) and an amount in cash equal to the par value thereof.  The White Hat Funds have the option to acquire in one or more additional closings an additional 9,500 shares of Series B Convertible Preferred Stock at $1,000 per share of Series B Convertible Preferred Stock. The source of the cash funds used to acquire the Additional Shares was the working capital of the White Hat Funds.

     

    Item 4. PURPOSE OF TRANSACTION
       
    Item 4 of the Schedule 13D is hereby amended and supplemented to include the following:
     
      First Amendment to Loan Agreement
       
      On October 25, 2024 (the “Closing Date”), certain funds affiliated with the Investment Manager (collectively, the “Lenders”) entered into that certain First Amendment (the “Loan Amendment”) to the Loan Agreement, with the Issuer, as borrower, Luna Technologies, Inc. and General Photonics Corp. as guarantors (together with the Issuer, the “Loan Parties”), and White Hat Lightning Opportunity LP, as agent (the “Agent”). The Loan Amendment provides for, among other things, the extension of certain incremental term facilities to the Issuer in an aggregate amount of $15,000,000 (the “Term Loans”), bringing the resulting total Term Loan commitment to $30,000,000, to provide funds for working capital and general corporate purposes of the Loan Parties.  The Loan Amendment provides that the Loan Agreement will mature on the earlier of (i) June 30, 2025, subject to possible extension if the Issuer meets certain milestones related to a Sale Transaction (as defined in the Loan Agreement), and (ii) the date on which a Sale Transaction closes.
       
      The Loan Amendment provides that the Loan Agreement will bear interest at a floating rate per annum equal to the Term SOFR (as defined in the Loan Amendment) plus a margin of 12%, with such interest payable monthly in cash in arrears, effective as of the Closing Date.
       

     

    CUSIP No. 550351100SCHEDULE 13D/APage 12 of 14 Pages

     

      In connection with the Loan Amendment, on the Closing Date, the Loan Parties, Lenders, Agent and PNC Bank, National Association (“PNC”) entered into that certain First Amendment (the “Subordination Agreement Amendment” and, together with that certain Fifth Amendment to the Loan Agreement, dated as of December 1, 2020 between the Loan Parties and PNC, the Loan Amendment and the other ancillary transaction documents executed in connection with the Loan Amendment, the “Transaction Documents”) to the Subordination and Intercreditor Agreement, dated as of July 19, 2024, to, among other things, restate the relative rights and priority of PNC and the Agent.
       
      The foregoing description of the Loan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Amendment. For further information regarding the Loan Amendment, reference is made to the full text of the Loan Amendment, which has been filed as Exhibit 99.5 hereto and incorporated by reference herein.
       
      Private Placement of Series B Convertible Preferred Stock
       
      In connection with the execution of the Transaction Documents, on the Closing Date, the holders (the “Holders”) of the Issuer’s Series B Convertible Preferred Stock entered into that certain Letter Agreement (the “Letter Agreement”) with the Issuer pursuant to which, among other things, the Holders (i) provided consent to the Issuer’s entry into the Transaction Documents (the “Preferred Consent”) as required by the terms of the outstanding Series B Convertible Preferred Stock and (ii) agreed to exercise a portion of their right to purchase, on a pro rata basis, and the Issuer agreed to issue and sell, 3,000 shares of the Series B Convertible Preferred Stock (the “Additional Shares”) in exchange for the Preferred Consent and an amount in cash equal to the par value thereof, in accordance with the Subscription Agreement, as amended by the Letter Agreement.
       
      Following the transaction described herein, the Holders have the option to acquire in one or more additional closings an additional 9,500 shares of Series B Convertible Preferred Stock at $1,000 per share of Series B Convertible Preferred Stock.
       
      The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement. For further information regarding the Letter Agreement, reference is made to the full text of the Letter Agreement, which has been filed as Exhibit 99.6 hereto and incorporated by reference herein.

     

     

    CUSIP No. 550351100SCHEDULE 13D/APage 13 of 14 Pages

     

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    Items 5(a) and (b) of the Schedule 13D are hereby amended and restated in their entirety:
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of shares of Common Stock and percentages of shares of Common Stock beneficially owned by each of the Reporting Persons, which includes accumulated dividends through October 25, 2024.  The percentages used in this Schedule 13D/A are calculated based upon an aggregate of 34,697,019 shares of Common Stock outstanding as of December 20, 2023, as described in the Subscription Agreement, and assumes the conversion of the shares of Series B Convertible Preferred Stock held by the White Hat Funds, subject to the Blocker.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition, which includes accumulated dividends through October 25, 2024.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
    Item 6 of the Schedule 13D is hereby amended and supplemented to include the following:
       
      The information set forth in Item 4 of Amendment No. 2 is hereby incorporated by reference.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS
       
    Item 7 of the Schedule 13D is hereby amended and supplemented to include the following:
       
    Exhibit 99.5 First Amendment to Loan Agreement, dated as of October 25, 2024, by and among the Company, Luna Technologies, Inc., General Photonics Corp., White Hat Lightning Opportunity LP and certain funds affiliated with White Hat Capital Partners LP (incorporated by reference to Exhibit 10.2 of the Issuer’s Current Report on Form 8-K filed with the SEC on October 29, 2024).
       
    Exhibit 99.6 Letter Agreement, dated as of October 25, 2024, by and among the Company and the Holders (incorporated by reference to Exhibit 10.3 of the Issuer’s Current Report on Form 8-K filed with the SEC on October 29, 2024).

     

     

     

    CUSIP No. 550351100SCHEDULE 13D/APage 14 of 14 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE:  October 29, 2024 /s/ David J. Chanley
      DAVID J. CHANLEY, (i) individually, (ii) as Managing Member of:  (a) WH Lightning GP LLC, (x) for itself and (y) as General Partner of White Hat Lightning Opportunity LP, (b) White Hat SP GP II LLC, (x) for itself and (y) as General Partner of White Hat Strategic Partners II LP, (c) WHSO GP LLC, (x) for itself and (y) as General Partner of White Hat Structured Opportunities LP and (d) White Hat Capital Partners GP LLC, as General Partner of White Hat Capital Partners LP.
       
      /s/ Mark R. Quinlan
      MARK R. Quinlan, individually

     

    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Stock to Be Suspended from Nasdaq Listing

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, due to the Company's inability to meet the March 27, 2025 deadline to file its previously disclosed delinquent filings with the Securities and Exchange Commission to regain compliance, the trading in its securities will be suspended tomorrow, January 7, 2025, and subsequently delisted from The Nasdaq Stock Market LLC ("Nasdaq"). Following the suspension, the Company expects its shares to be eligible to trade on the over-the-counter ("OTC") market, specifically the OTC Expert Market. The suspension/delisting of the Company's stock from Nasdaq does not

      1/6/25 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Financials

    Live finance-specific insights

    See more
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care